Cargando…

Angiotensin converting enzyme gene polymorphism in type 2 diabetics with nephropathy

Detalles Bibliográficos
Autores principales:	Naresh, V. V. S., Reddy, A. L. K., Sivaramakrishna, G., Sarma, P. V. G. K., Vardhan, R. V., Kumar, V. S.
Formato:	Texto
Lenguaje:	English
Publicado:	Medknow Publications 2010
Materias:	Letter to Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2931132/ https://www.ncbi.nlm.nih.gov/pubmed/20835335 http://dx.doi.org/10.4103/0971-4065.65314

Ejemplares similares

Angiotensin converting enzyme gene polymorphism in type II diabetics with nephropathy
por: Naresh, V. V. S., et al.
Publicado: (2009)

Angiotensin-converting Enzyme Genetic Polymorphism
por: Wiwanitkit, Somsri, et al.
Publicado: (2014)

Angiotensin converting enzyme gene polymorphism and influence of ACE inhibition
por: Arman, Q.
Publicado: (2010)

Role of angiotensin converting enzyme and angiotensinogen gene polymorphisms in angiotensin converting enzyme inhibitor-mediated antiproteinuric action in type 2 diabetic nephropathy patients
por: Aggarwal, Neerja, et al.
Publicado: (2017)

ACE polymorphism and diabetic nephropathy
por: Wiwanitkit, V.
Publicado: (2010)

A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy
por: Pathak, Jahnavi V., et al.
Publicado: (2015)

Polymorphism of Angiotensin-Converting Enzyme (rs4340) and Diabetic Nephropathy in Caucasians with Type 2 Diabetes Mellitus
por: Šeruga, M, et al.
Publicado: (2016)

An observed association between angiotensin-converting enzyme 2 polymorphisms and COVID-19 severity in China
por: Wang, Jin, et al.
Publicado: (2022)

Angiotensin-converting enzyme G2350A gene polymorphisms and hypertension among patients with intracerebral hemorrhage
por: Joob, Beuy, et al.
Publicado: (2019)

Angiotensin-converting enzyme 2, sex differences, and COVID-19: The missing link
por: Van den Eynde, Jef, et al.
Publicado: (2021)

Angiotensin‐converting enzyme gene variants interact with the renin–angiotensin system pathway to confer risk and protection against type 2 diabetic retinopathy
por: Cheema, Balneek Singh, et al.
Publicado: (2013)

Renin Angiotensin Converting Enzyme 2 and COVID-19: Prevention and Treatment
por: Kafami, Marzieh, et al.
Publicado: (2021)

COVID-19 and angiotensin-converting enzyme inhibitors from plant origin
por: Gharebaghi, Reza, et al.
Publicado: (2022)

A review of urinary angiotensin converting enzyme 2 in diabetes and diabetic nephropathy
por: Gilbert, Akankwasa, et al.
Publicado: (2018)

Angiotensin converting enzyme polymorphism and ischemic stroke
por: Salem, Gelan M., et al.
Publicado: (2020)

Smoking and Angiotensin-converting Enzyme Inhibitor/Angiotensin Receptor Blocker Cessation to Limit Coronavirus Disease 2019
por: Rossato, Marco, et al.
Publicado: (2020)

Angiotensin-converting enzyme inhibitors and angiotensin receptor blocker in coronavirus disease 2019: Safe and possibly beneficial
por: Gupta, Nitesh, et al.
Publicado: (2020)

To do or not to do: Angiotensin converting enzyme inhibitors/angiotensin receptor blocker in COVID-19 elderly patients
por: Vura, Naga Venkata Rama Krishna, et al.
Publicado: (2021)

Posttransplant lymphoproliferative disease presenting as jejunal perforation
por: Krishna, K. C., et al.
Publicado: (2009)

Determinants of circulating angiotensin-converting enzyme 2 protein levels in the general population
por: Kuznetsova, Tatiana, et al.
Publicado: (2021)

Another perspective for COVID-19 pandemic: Angiotensin-converting enzyme 2 and ethnicity
por: Simsek, Feride Irem, et al.
Publicado: (2020)

Angiotensin converting enzyme inhibitors and angiotensin receptor blockers improved the outcome of patients with severe COVID-19 and hypertension
por: Meng, Xiao, et al.
Publicado: (2020)

Re: Is there a difference in the effect between the angiotensin‐converting enzyme inhibitor and angiotensin‐receptor blocker on the COVID‐19?
por: Liu, Xiao, et al.
Publicado: (2020)

Angiotensin-converting enzyme activity and inhibition in dogs with cardiac disease and an angiotensin-converting enzyme polymorphism
por: Meurs, Kathryn M, et al.
Publicado: (2017)

What Is the Role of Angiotensin-Converting Enzyme 2 (ACE2) in COVID-19 Infection in Hypertensive Patients With Diabetes?
por: John, Thadathilankal-Jess, et al.
Publicado: (2020)

Does angiotensin-converting enzyme polymorphism have association with symptomatic benign prostatic hyperplasia?
por: Bid, Hemant Kumar, et al.
Publicado: (2010)

Effectiveness of C1-INH therapy in angiotensin converting enzyme inhibitor induced angioedema
por: Kovaltchouk, Uliana, et al.
Publicado: (2021)

Reply to “Angiotensin-converting enzyme 2, sex differences, and COVID-19: The missing link”
por: Elgendy, Islam Y., et al.
Publicado: (2021)

Reduction of microalbuminuria in type-2 diabetes mellitus with angiotensin-converting enzyme inhibitor alone and with cilnidipine
por: Singh, V. K., et al.
Publicado: (2015)

Cognitive enhancing effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on learning and memory
por: Nade, V. S., et al.
Publicado: (2015)

Angiotensin Converting Enzymes
por: Wong, Marty K.S.
Publicado: (2016)

Why angiotensin converting enzyme inhibitors and angiotensin II receptor blockers are not prescribed in the management of hypertension among hemodialysis patients in India
por: Mateti, Uday Venkat, et al.
Publicado: (2014)

Tissue Specificity of Human Angiotensin I-Converting Enzyme
por: Kryukova, Olga V., et al.
Publicado: (2015)

Association of Angiotensin-Converting Enzyme Gene Polymorphisms and Nephropathy in Diabetic Patients at a Tertiary Care Centre in South India
por: Wyawahare, Mukta, et al.
Publicado: (2017)

Angiotensin-Converting Enzyme 2 as the Molecular Bridge Between Epidemiologic and Clinical Features of COVID-19
por: Bombardini, Tonino, et al.
Publicado: (2020)

Stimulation of Angiotensin Converting Enzyme 2: A Novel Treatment Strategy for Diabetic Nephropathy
por: Nomura, Haru, et al.
Publicado: (2022)

Letter to the editors in response to: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic (Cure et al.)
por: Ekiz, Timur, et al.
Publicado: (2020)

Renin‐angiotensin aldosterone profile before and after angiotensin‐converting enzyme‐inhibitor administration in dogs with angiotensin‐converting enzyme gene polymorphism
por: Adin, Darcy, et al.
Publicado: (2020)

Angiotensin-converting-enzyme inhibitors (ACE inhibitors) and angiotensin II receptor blocker (ARB) use in COVID-19 prevention or treatment: A paradox
por: Javanmard, Shaghayegh Haghjooy, et al.
Publicado: (2020)

Podocyte-specific overexpression of human angiotensin-converting enzyme 2 attenuates diabetic nephropathy in mice
por: Nadarajah, Renisha, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_vu09o7rcdtcj08p4ce7lemtld5